Andere talen AbbVie Inc.

Aandelen

ABBV

US00287Y1091

Farmaceutische producten

Beurs gesloten - Nyse Andere beurzen 22:00:02 13-12-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
173,37 ^USD	+0,10%		-1,60%	+11,87%

13/12	AbbVie koopt Nimble Therapeutics	MT
12/12	Contactlenzenmaker Bausch + Lomb zegt verkoop te overwegen	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

AbbVie Buying Nimble Therapeutics for $200 Million to Boost Immunology Pipeline	13/12
AbbVie to Buy Nimble Therapeutics	13/12
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline	13/12
AbbVie Inc. entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million.	13/12
Contact lens maker Bausch + Lomb says it is exploring sale	12/12
Vraylar sales growth seen slowing in 2025, says Richter CEO	12/12
AbbVie : finalise l'acquisition d'Aliada Therapeutics.	11/12
AbbVie Closes Aliada Therapeutics Acquisition	11/12
AbbVie Completes Acquisition of Aliada Therapeutics	11/12
AbbVie Inc. complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures.	11/12
AbbVie Reports Durable Results from Mono, Combo Therapy for Blood Cancer	09/12
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma	09/12
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update	09/12
Correction to AbbVie Tavapadon Phase 3 Study Article	09/12
AbbVie - Investigational Epcoritamab Combination Therapy Shows High Response Rates in Clinical Trial of Patients with Relapsed or Refractory Follicular Lymphoma	09/12
AbbVie's Phase 3 Trial of Tavapadon for Parkinson's Disease Meets Endpoints	09/12
AbbVie's Tavapadon Hits Key Goals in Second Phase 3 Parkinson's Study	09/12
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease	09/12
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease	09/12
AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab	08/12
Data Center-Boom: Wer profitiert?	06/12
Wall Street's gravity-defying rally awaits non-farm payrolls verdict	05/12
Índices: Un repaso a los selectivos nórdicos	05/12
Analyst recommendations: Applovin, Chewy, Netflix, Deliveroo, Diageo...	05/12
Indici: petrolio, salute, industria... indici tipicamente nordici	04/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen AbbVie Inc.

Aandelen

ABBV

US00287Y1091

Farmaceutische producten

Andere talen

Filters